Showing results (61-70 of 165) with videos related to

Sort By:
Pageof 17
Leukemia Research|December 4, 2012
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS studyCarlos Besses, Jean-Jacques Kiladjian, Martin Griesshammer, et al.
The Australian Journal of Rural Health|May 19, 2015
Longlook: initial outcomes of a longitudinal integrated rural clinical placement programScott Kitchener, Renee Day, Daniel Faux, et al.
Future Oncology (London, England)|February 6, 2025
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study designJohn Mascarenhas, Keri Maher, Raajit Rampal, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
FunctionaL Assigning Sequence Homing (FLASH) maps phenotype to sequence with deep and machine learningDaniel J Cotter, Marie-Claire Harrison, Arjun Rustagi, et al.
BJGP Open|July 30, 2024
Pathways to myeloproliferative neoplasm presentation and time to diagnosis: results from a cross-sectional studyEmma-Louise Tarburn, Lisa Iversen, Charlotte Robertson, et al.
Leukemia & Lymphoma|July 26, 2016
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyureaGenevieve Douglas, Claire Harrison, Cecily Forsyth, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2006
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasisMelanie J Percy, Quan Zhao, Adrian Flores, et al.
Genome Research|July 10, 2021
Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasmsStephania Contreras Castillo, Bertille Montibus, Azucena Rocha, et al.
Blood Advances|July 8, 2020
Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding studyVikas Gupta, Denise Wolleschak, Hans Hasselbalch, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Pageof 17